The US Food and Drug Administration is considering whether new regulatory pathways are needed for certain types of human cells, tissues, and cellular and tissue-based products (HCT/Ps).
What types of HCT/Ps might fall into this new category, and what any new regulatory pathway might look like, remains to be seen. However, the agency’s public announcement that it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?